The Oncology Institute, Inc.
TOIHealthcareNASDAQMedical Care Facilities · Last scanned Jul 18, 2026
Scan Results
Daily timeframeThe Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. With a market capitalization of $534.9M, it sits in small-cap territory. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
Market Cap
$534.9M
Beta
0.39
P/E (TTM)
—
P/E (Fwd)
-33.44
EPS (TTM)
$-0.36
EPS (Fwd)
$-0.16
ROE
—
ROA
-12.3%
Cash
$30.3M
Total Debt
$104.9M
Free CF
-$15.3M
52W Change
52.9%
Annual Financials
Cash vs Debt
The Oncology Institute, Inc. carries $104.9M in total debt against $30.3M in cash reserves — debt is roughly 3.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$15.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $252.5M (2022) to $502.7M (2025), reflecting a 99% increase over the period.
TOI's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TOI.